NEW YORK (GenomeWeb) – Following Illumina's miss on the consensus Wall Street estimate for its revenues, investment bank Janney Montgomery Scott today downgraded shares of the firm to a Neutral rating from a previous Buy rating. 

"With revenue growth decelerating, we see limited expansion to the 50.4X" price/earning multiple for Illumina in 2017, analyst Paul Knight wrote in a research note. He maintained the fair value of Illumina's shares at $240. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.